Group 1 - Huajian Medical (01931) shares rose over 13%, reaching 10.98 HKD with a trading volume of 45.65 million HKD [1] - The company announced a conditional agreement to acquire 20.31% of Guofu Quantum's shares for approximately 3.142 billion HKD, to be paid through the issuance of consideration shares [1] - This acquisition aims to enhance capital synergy, promote the implementation of RWA ecosystem, and build an innovative cooperation network to support the globalization of Chinese assets [1] Group 2 - Since late July, Huajian Medical has launched several key strategic initiatives, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [2] - The company is pursuing a stablecoin license for its U.S. subsidiary and has partnered with BGI's subsidiary to establish the world's first "innovative drug intellectual property tokenization fund" [2] - On August 8, Huajian Medical initiated the "Global Enhanced Ethereum (ETH) Treasury" strategy, collaborating with licensed exchange HashKey and completing a compliant purchase of 149 million HKD in ETH [2] - The company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the RWA trading platform [2]
华检医疗再涨超13% 拟斥超31亿港元收购国富量子20.31股份 持续推动RWA生态落地